European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer
1 Department of Obstetrics and Gynecology, Kahramanmaras Sutcu Imam University, Kahramanmaras (Turkey)
2 Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, PA (USA);
3 Division of Gynecologic Oncology, Uludag University, Bursa (Turkey)
4 Mount Sinai Medical Center, Department of Obstetrics and Gynecology, NY (USA)
5 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY
6 Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY (USA)
Eur. J. Gynaecol. Oncol. 2013, 34(6), 522–526;
Published: 10 December 2013
Introduction: The optimum follow-up regimen after treatment for early-stage endometrial cancer with curative intent is unknown. The National Comprehensive Cancer Network recommends a physical exam and vaginal cytology every three to six months for two years then at six to 12 month intervals with annual chest X-rays (CXR). However, there is debate as to whether intensive follow-up results in an improvement in outcomes for those with recurrent endometrial cancer. Objective: To determine if intensive surveillance for recurrent cancer in women with early-stage endometrial cancer improves their outcomes. Materials and Methods: The Roswell Park Cancer Institute tumor registry was used to identify patients with Stage I and II endometrial cancer initially diagnosed and treated over an 18-year period, who subsequently recurred. Clinico-pathological variables were abstracted. Patients were divided into two groups, depending on their mode of diagnosis of recurrent cancer: 1) routine screening, or 2) symptomatic. The outcomes between the two groups were compared. Results: Fifty-two patients met inclusion criteria. Twenty-three patients were diagnosed via routine screening methods and 29 were symptomatic at presentation. Groups were equally represented with respect to age, stage, grade, adjuvant therapy, site of recurrence (local, distant), and time to recurrence (p > 0.05). Median survival time was 79 months for those diagnosed during routine screening and 80 months for symptomatic patients (p > 0.05). Conclusion: Pap smear and CXR appear to be of limited utility as the present study has shown that women diagnosed as a result of intensive surveillance did not have a better outcome than those who presented when symptomatic.